MarketCap
Facebook
X
Telegram
Solid Biosciences Interest Expense | SLDB
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Solid Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 824 K | 652 K | 1.1 M | -381 K | 2 K | 1 K | 515 K | 270 K | 1 M | 271 K | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.1 M | -381 K | 425 K |
Quarterly Interest Expense Solid Biosciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 214 K | 214 K | 157 K | 219 K | 210 K | 207 K | 188 K | 199 K | 211 K | 239 K | 3 K | 270 K | 278 K | 265 K | 282 K | -355 K | -13 K | -3 K | -10 K | - | - | 3 K | - | - | - | 1 K | 1 K | 170 K | 56 K | 77 K | 212 K | 83 K | 38 K | 118 K | 31 K | - | 228 K | 504 K | 176 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 504 K | -355 K | 136 K |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
38.2 M | $ 0.61 | 3.09 % | $ 182 M |  Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
13 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
501 K | - | - | $ 36.6 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M | USA |
 |
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
27 K | - | - | $ 55.5 M | USA |
 |
Pacira BioSciences
PCRX
|
-6.62 M | $ 36.47 | -0.07 % | $ 1.63 B | USA |
 |
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
-13.2 M | $ 16.54 | -1.78 % | $ 2.29 B | USA |
 |
Sundial Growers
SNDL
|
81 K | $ 1.42 | 1.84 % | $ 366 M | Canada |
 |
Tilray
TLRY
|
29.9 M | $ 2.61 | -1.7 % | $ 292 M | Canada |
 |
Veru
VERU
|
768 K | $ 2.13 | 0.71 % | $ 31.2 M | USA |
 |
Viatris
VTRS
|
471 M | $ 21.07 | 1.06 % | $ 24.2 B | USA |
 |
cbdMD
YCBD
|
34.3 K | $ 0.4 | 4.03 % | $ 1.61 M | USA |
 |
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M |  Irlanda |
 |
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | USA |
 |
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.65 K | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
27.3 K | $ 0.54 | -2.0 % | $ 2.32 M |  China |
 |
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | USA |
 |
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | USA |
 |
DURECT Corporation
DRRX
|
2.4 M | - | - | $ 50.1 M | USA |
 |
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | USA |
 |
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | USA |
 |
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | USA |
 |
Harrow Health
HROW
|
47 K | $ 29.21 | -3.79 % | $ 1.07 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
496 K | $ 6.11 | 15.19 % | $ 90.8 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.15 M | $ 4.45 | 4.1 % | $ 176 M | USA |
 |
Emergent BioSolutions
EBS
|
54.2 M | $ 6.04 | -0.08 % | $ 323 M | USA |
 |
Cronos Group
CRON
|
-241 K | $ 3.45 | 1.17 % | $ 1.32 B | Canada |
 |
Evolus
EOLS
|
-539 K | $ 7.42 | 8.88 % | $ 478 M | USA |
 |
Organogenesis Holdings
ORGO
|
-5 K | $ 1.05 | 11.74 % | $ 133 M | USA |
 |
Bausch Health Companies
BHC
|
-142 M | $ 8.36 | 0.78 % | $ 3.1 B | Canada |
 |
Rockwell Medical
RMTI
|
-623 K | $ 7.05 | -3.56 % | $ 254 M | USA |
 |
SCYNEXIS
SCYX
|
3.13 M | $ 3.42 | -2.75 % | $ 171 M | USA |
 |
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
16 K | $ 1.23 | 7.89 % | $ 2.07 M | USA |
 |
TherapeuticsMD
TXMD
|
300 K | $ 1.85 | 6.32 % | $ 21.4 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
134 K | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
2.78 M | - | - | $ 150 M | USA |
 |
Jupiter Wellness
JUPW
|
152 K | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
-174 K | - | - | $ 5.07 M | USA |